Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | DRD3 | P35462 | 3/20 | 0.40 |
| ▸ | VCP | P55072 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25819363 | 0.91 | HRH3 (0.44) | HRH3KCNH2CYP2D6PIK3CDDRD2 | |
| SCHEMBL22520728 | 0.87 | HRH3 (0.43) | HRH3KCNH2CYP2D6DRD2DRD3 | |
| SCHEMBL22520683 | 0.86 | PIK3CD (0.41) | HRH3KCNH2CYP2D6PIK3CDVCP | |
| SCHEMBL24475306 | 0.85 | HRH3 (0.42) | HRH3KCNH2CYP2D6DRD2DRD3 | |
| SCHEMBL18705111 | 0.84 | HRH3 (0.48) | HRH3KCNH2CYP2D6PIK3CD | |
| SCHEMBL26295687 | 0.84 | HRH3 (0.50) | HRH3KCNH2CYP2D6DRD2DRD3 | |
| SCHEMBL20046477 | 0.84 | VCP (0.44) | HRH3KCNH2CYP2D6DRD2DRD3 | |
| SCHEMBL26263767 | 0.83 | HRH3 (0.50) | HRH3KCNH2CYP2D6DRD2DRD3 | |
| SCHEMBL25075241 | 0.82 | PIK3CD (0.40) | PIK3CDDRD2DRD3SIGMAR1CHRM3 | |
| SCHEMBL24952354 | 0.82 | VCP (0.43) | HRH3KCNH2CYP2D6DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ASTRAZENECA UK LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ESR1, GPER1, ESRRG | HRH3 1546/4885KCNH2 3717/4885CYP2D6 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.